Organizers: China Medical and Health Products Import and Export Chamber of Commerce, Shanghai Bohua Exhibition Co., Ltd
Period: Annual Exhibition Area: 20,000 square exhibitors Number: 300 Number of visitors: 20,000 people
In recent years, under the guidance of the national innovation-driven strategy, the pharmaceutical ecological environment has under changed dramatically and is leading the development of China's pharmaceutical industry into a new era of innovation. After the baptism of the new crown pneumonia epidemic, China's pharmaceutical industry won, with innovation as the engine, to achieve the "13th Five-Year" successful conclusion. Looking back on 2020, China approved 14 first-class innovative drugs, and then a new high. Local innovative drugs overseas licensing transactions nearly 20, gradually towards normal, the internationalization process is steadily forward. China's independent innovation, to show the world the real power, but also ran out of a new speed. Facing the change of competition pattern, the improvement of innovation threshold, in order to stand out in the high-level competition, only continue to add code innovation technology, deeply tap the potential value, to patients' clinical needs as the center, to differentiated research and development can seek a new breakthrough in previous series of conference speakers (ranked in no order). To this end, in order to help Chinese pharmaceutical enterprises continue to innovate, homeopathically and to a higher level, CPhI China launched the "Thinking And Enjoy" - 2021 New Drug Research and Development and CMC Summit Forum, with the theme of "Exciting the Great Era, Sailing the New Decade", inviting Chinese pharmaceutical innovation leaders to discuss the new era of pharmaceutical innovation, focus on the frontier, discuss strategies, share dry goods, solid foundation. In the new year, CPhI Will be accompanied by innovation and development in china's pharmaceutical industry. CPhI "Enjoy" is a value-sharing platform created by the China Medical and Health Products Import and Export Chamber of Commerce in cooperation with Shanghai Bohua International Exhibition Co., Ltd. to serve the Chinese pharmaceutical industry and focus on pharmaceutical innovation. CPhI China has become an annual event for the pharmaceutical industry in China, and the CPhI "Thinking Fair" will bring together the exclusive crowd of pharmaceutical innovation, for pharmaceutical innovation "thinkers" to convey new ideas, stimulate new vitality, focus on new development.
The scope of the exhibits
Forum related: small molecule new pharmaceutical projects, design and development, biomoglyte pharmaceutical projects, design and development, pharmaceutical packaging and accessories policy analysis, pharmaceutical companies, biotechnology companies, CRO/CDMO enterprises, academic and scientific research institutions, institutions of higher learning, government departments, industry associations, investment/law firms/advisory bodies, technology and solutions providers
2024年
展会时间:待定
展会地点:待定
2025年
展会时间:待定
展会地点:待定
2026年
展会时间:待定
展会地点:待定
CPhI新药研发与CMC高峰论坛
图片
CPhI新药研发与CMC高峰论坛在中国 - 上海 举行;
主办单位: 中国医药保健品进出口商会、上海博华展览有限公司
论坛相关: 小分子新药立项、设计与开发;生物大分子药立项、设计与开发;药用包装与辅料政策分析;制药企业、生物科技公司、CRO/CDMO企业、学术及科研机构、高等院校、政府部门、行业协会、投资/律所/咨询机构、技术及解决方案提供商
Organizers: China Medical and Health Products Import and Export Chamber of Commerce, Shanghai Bohua Exhibition Co., Ltd
Period: Annual Exhibition Area: 20,000 square exhibitors Number: 300 Number of visitors: 20,000 people
In recent years, under the guidance of the national innovation-driven strategy, the pharmaceutical ecological environment has under changed dramatically and is leading the development of China's pharmaceutical industry into a new era of innovation. After the baptism of the new crown pneumonia epidemic, China's pharmaceutical industry won, with innovation as the engine, to achieve the "13th Five-Year" successful conclusion. Looking back on 2020, China approved 14 first-class innovative drugs, and then a new high. Local innovative drugs overseas licensing transactions nearly 20, gradually towards normal, the internationalization process is steadily forward. China's independent innovation, to show the world the real power, but also ran out of a new speed. Facing the change of competition pattern, the improvement of innovation threshold, in order to stand out in the high-level competition, only continue to add code innovation technology, deeply tap the potential value, to patients' clinical needs as the center, to differentiated research and development can seek a new breakthrough in previous series of conference speakers (ranked in no order). To this end, in order to help Chinese pharmaceutical enterprises continue to innovate, homeopathically and to a higher level, CPhI China launched the "Thinking And Enjoy" - 2021 New Drug Research and Development and CMC Summit Forum, with the theme of "Exciting the Great Era, Sailing the New Decade", inviting Chinese pharmaceutical innovation leaders to discuss the new era of pharmaceutical innovation, focus on the frontier, discuss strategies, share dry goods, solid foundation. In the new year, CPhI Will be accompanied by innovation and development in china's pharmaceutical industry. CPhI "Enjoy" is a value-sharing platform created by the China Medical and Health Products Import and Export Chamber of Commerce in cooperation with Shanghai Bohua International Exhibition Co., Ltd. to serve the Chinese pharmaceutical industry and focus on pharmaceutical innovation. CPhI China has become an annual event for the pharmaceutical industry in China, and the CPhI "Thinking Fair" will bring together the exclusive crowd of pharmaceutical innovation, for pharmaceutical innovation "thinkers" to convey new ideas, stimulate new vitality, focus on new development.
The scope of the exhibits
Forum related: small molecule new pharmaceutical projects, design and development, biomoglyte pharmaceutical projects, design and development, pharmaceutical packaging and accessories policy analysis, pharmaceutical companies, biotechnology companies, CRO/CDMO enterprises, academic and scientific research institutions, institutions of higher learning, government departments, industry associations, investment/law firms/advisory bodies, technology and solutions providers